Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2008-10-13 Board/Management Inform…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming shareholders appoint Sijmen de Vries as new CEO
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the appointment of Dr. Sijmen de Vries as the new CEO, effective November 3, 2008, succeeding Dr. Francis J. Pinto. It details the transition plan and mentions shareholder approval at an Extraordinary Meeting (EGM) for the appointment and remuneration changes. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2008-10-13 English
Pharming's Board of Supervisory Directors nominates new CEO
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the nomination of a new CEO (Dr Sijmen de Vries) to succeed the retiring CEO (Dr Francis J. Pinto). This directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management. The document explicitly discusses the transition plan and the proposed appointment date at an Extraordinary General Meeting of Shareholders. Therefore, the appropriate code is MANG.
2008-09-26 English
Pharming provides Business update at UBS Conference
Investor Presentation Classification · 95% confidence The document is titled "PHARMING PROVIDES BUSINESS UPDATE AT UBS CONFERENCE" and details progress on a product (Rhucin®), addressing regulatory concerns (CHMP/EMEA), and outlining future submission plans (BLA/FDA). This content is characteristic of an update provided to investors, often presented at a conference. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is a presentation of business and product development information aimed at investors. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (4264 chars) is substantial enough to be the presentation content itself, not just a brief announcement of one.
2008-09-25 English
Pharming to present at UBS Global Life Sciences Conference
Investor Presentation Classification · 95% confidence The document is a short press release dated September 17, 2008, announcing that the CEO of Pharming Group NV will be presenting at the UBS Global Life Sciences Conference on September 22, 2008. It provides details about the presentation time and location, and mentions that the presentation will be made available on the company website afterward. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing detailing results (like ER or MRQ). It is an announcement about an upcoming investor event where the company will present its information. This fits best under Investor Presentation (IP) if the presentation itself was attached, but since this is just the announcement of the presentation, and it is a general communication to investors about an event, it aligns closely with the intent of an Investor Presentation announcement or a general regulatory announcement. Given the options, the content is about an upcoming presentation to investors. However, following Rule 2 (The 'MENU VS MEAL' Rule), if this were the presentation itself, it would be IP. Since it is merely an announcement that the company *will present* and the presentation *will be made available later*, it is a general announcement regarding investor relations activities. The most fitting category for an announcement about an upcoming investor presentation, especially when the actual presentation material is not included, is often the general Regulatory Filings (RNS) or potentially Investor Presentation (IP) if we interpret it as a precursor. Given the nature of announcing participation in a conference, RNS is a safe fallback, but since the core subject is an investor presentation, IP is a strong candidate if we consider the intent. Let's re-evaluate: It announces participation in a conference where an update will be given. This is a standard corporate communication. If the document were longer and contained the slides, it would be IP. As a short announcement about an upcoming event, RNS (Regulatory Filings/General Announcement) is appropriate, but since the subject is explicitly about presenting information to investors, IP is more specific if we allow for announcements *about* presentations. Given the strict definitions, RNS is the most neutral fit for a short announcement about a future event, but since the event is an investor presentation, I will lean towards IP as the subject matter is highly specific to investor materials, even if it's just the announcement.
2008-09-18 English
Pharming to present at UBS Global Life Sciences Conference
Regulatory Filings Classification · 85% confidence The document is a short press release announcing that the company's CEO will present an update on the company and its business at the upcoming UBS Global Life Sciences Conference. This type of announcement, which details participation in an investor event rather than releasing periodic financial results (ER) or a full presentation document (IP), is best classified as a general announcement related to investor relations. Given the options, and since it is an announcement about an upcoming event where company information will be shared, it most closely aligns with a general regulatory/investor announcement. However, since the content is specifically about presenting company updates at a conference, it is a form of investor communication. It is not a full presentation (IP), nor an earnings release (ER). It is a notification about an investor event. The closest fit among the specific categories is difficult, but since it is an announcement about company business updates being shared with investors at a conference, and it is not a formal regulatory filing like 10-K or a specific report, it falls under general investor communication. Given the definitions, it is not a proxy (PSI), dividend notice (DIV), or management change (MANG). It is an announcement of an event where company information will be shared. If we consider 'Investor Presentation' (IP) as the material *given* at the event, this document is the *announcement* of that event. Since there is no specific 'Conference Presentation Announcement' code, and it is a brief announcement, it is most appropriately categorized as a general Regulatory Filing (RNS) or potentially related to Investor Presentation (IP) if the announcement itself is considered the primary communication vehicle, but RNS is the best fallback for non-standard announcements. Given the context of investor events, RNS is the most appropriate general category for this type of brief corporate update announcement.
2008-09-18 English
FDA authorizes Investigational New Drug application for recombinant human C1 inhibitor in kidney transplantation
Regulatory Filings Classification · 95% confidence The document is a press release written in Dutch announcing that the US FDA has approved an Investigational New Drug (IND) application for a clinical trial involving Pharming Group NV's recombinant human C1 inhibitor (rhC1INH) for kidney transplant rejection. This type of announcement, detailing regulatory milestones (IND approval) and clinical trial plans, is characteristic of an announcement regarding corporate activities or regulatory progress, but it is not a formal financial report (like 10-K or IR) nor a transcript or presentation. It is a specific corporate update. Given the options, it most closely aligns with a general regulatory announcement or a specific corporate action update. Since it is an announcement about a regulatory approval (IND application approval) and not a full financial report, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-financial regulatory event announcement, or potentially 'Capital/Financing Update' (CAP) if the IND approval was tied to a financing event, but RNS is the best fit for general regulatory news not covered by other specific codes like DIRS or DIV. The length (4895 chars) suggests it is a full announcement, not just a brief RPA.
2008-09-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.